These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19644468)

  • 1. IL-1beta-targeted antibody approved for rare autoinflammatory disorders.
    Nat Rev Drug Discov; 2009 Aug; 8(8):605. PubMed ID: 19644468
    [No Abstract]   [Full Text] [Related]  

  • 2. Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases.
    Bettiol A; Lopalco G; Emmi G; Cantarini L; Urban ML; Vitale A; Denora N; Lopalco A; Cutrignelli A; Lopedota A; Venerito V; Fornaro M; Vannacci A; Rigante D; Cimaz R; Iannone F
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1beta and the autoinflammatory diseases.
    Dinarello CA
    N Engl J Med; 2009 Jun; 360(23):2467-70. PubMed ID: 19494224
    [No Abstract]   [Full Text] [Related]  

  • 4. Canakinumab for the treatment of familial Mediterranean fever.
    Ozdogan H; Ugurlu S
    Expert Rev Clin Immunol; 2017 May; 13(5):393-404. PubMed ID: 28362189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The challenge of autoinflammatory syndromes: with an emphasis on hyper-IgD syndrome.
    van der Meer JW; Simon A
    Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii23-ii29. PubMed ID: 27856657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
    De Benedetti F; Gattorno M; Anton J; Ben-Chetrit E; Frenkel J; Hoffman HM; Koné-Paut I; Lachmann HJ; Ozen S; Simon A; Zeft A; Calvo Penades I; Moutschen M; Quartier P; Kasapcopur O; Shcherbina A; Hofer M; Hashkes PJ; Van der Hilst J; Hara R; Bujan-Rivas S; Constantin T; Gul A; Livneh A; Brogan P; Cattalini M; Obici L; Lheritier K; Speziale A; Junge G
    N Engl J Med; 2018 May; 378(20):1908-1919. PubMed ID: 29768139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canakinumab induces remission in a patient with resistant familial Mediterranean fever.
    Hacihamdioglu DO; Ozen S
    Rheumatology (Oxford); 2012 Jun; 51(6):1041. PubMed ID: 22403182
    [No Abstract]   [Full Text] [Related]  

  • 8. Update on Auto-Inflammatory Diseases and Familial Mediterranean Fever.
    Berkun Y; Eisenstein EM
    Isr Med Assoc J; 2016; 18(3-4):221-4. PubMed ID: 27228648
    [No Abstract]   [Full Text] [Related]  

  • 9. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis.
    Mitroulis I; Skendros P; Oikonomou A; Tzioufas AG; Ritis K
    Ann Rheum Dis; 2011 Jul; 70(7):1347-8. PubMed ID: 21345814
    [No Abstract]   [Full Text] [Related]  

  • 10. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature.
    Meinzer U; Quartier P; Alexandra JF; Hentgen V; Retornaz F; Koné-Paut I
    Semin Arthritis Rheum; 2011 Oct; 41(2):265-71. PubMed ID: 21277619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment.
    Alpa M; Roccatello D
    Drug Des Devel Ther; 2015; 9():1983-7. PubMed ID: 25945034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosage Considerations for Canakinumab in Children With Periodic Fever Syndromes.
    Zhuang L; Chen J; Yu J; Marathe A; Sahajwalla C; Borigini M; Maynard J; Burckart GJ; Wang Y
    Clin Pharmacol Ther; 2019 Sep; 106(3):557-567. PubMed ID: 30447083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of canakinumab in the cryopyrin-associated periodic syndrome.
    Lachmann HJ; Kone-Paut I; Kuemmerle-Deschner JB; Leslie KS; Hachulla E; Quartier P; Gitton X; Widmer A; Patel N; Hawkins PN;
    N Engl J Med; 2009 Jun; 360(23):2416-25. PubMed ID: 19494217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canakinumab as monotherapy for treatment of familial Mediterranean fever - first report in Central and Eastern Europe region.
    Jesenak M; Hrubiskova K; Kapustova L; Kostkova M; Banovcin P
    Bratisl Lek Listy; 2018; 119(4):198-200. PubMed ID: 29663815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of familial Mediterranean fever: colchicine and beyond.
    Gül A
    Isr Med Assoc J; 2014 May; 16(5):281-4. PubMed ID: 24979831
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
    Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
    Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canakinumab for the treatment of cryopyrin-associated periodic syndromes.
    Walsh GM
    Drugs Today (Barc); 2009 Oct; 45(10):731-5. PubMed ID: 20069137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canakinumab (Ilaris) for systemic juvenile idiopathic arthritis.
    Med Lett Drugs Ther; 2013 Aug; 55(1423):65-6. PubMed ID: 23959387
    [No Abstract]   [Full Text] [Related]  

  • 19. [Canakinumab, a monoclonal antibody against IL-1β, with potential utility in different inflammatory processes].
    Carné X
    Med Clin (Barc); 2011 Jan; 136 Suppl 1():34-7. PubMed ID: 21596185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis.
    Kisla Ekinci RM; Balci S; Dogruel D; Altintas DU; Yilmaz M
    Paediatr Drugs; 2019 Oct; 21(5):389-395. PubMed ID: 31463794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.